DOCSLIB.ORG

Microwave Heating Unit and Method

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Microwave Heating Unit and Method (19) *EP003747289A1* (11) EP 3 747 289 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 09.12.2020 Bulletin 2020/50 A24F 47/00 (2020.01) A61M 15/06 (2006.01) H05B 6/80 (2006.01) (21) Application number: 19178687.0 (22) Date of filing: 06.06.2019 (84) Designated Contracting States: (72) Inventors: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB • KÜHN, Silvio GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO 16348 Wandlitz (DE) PL PT RO RS SE SI SK SM TR • DUMLER, Ralf Designated Extension States: 1870 Monthey (CH) BA ME • TORREÑO NÚÑEZ, Alberto Designated Validation States: 6890 Lustenau (AT) KH MA MD TN (74) Representative: Hoefer & Partner Patentanwälte (71) Applicant: Torrenño Núñez, Alberto mbB 6890 Lustenau (AT) Pilgersheimer Straße 20 81543 München (DE) (54) MICROWAVE HEATING UNIT AND METHOD (57) The present invention refers to a microwave figured to receive and hold a sample (2) in a holding and heating method and unit (1) for heating an aerosol-form- exposing space (15) and to expose the sample (2) to a ing sample (2) due to microwave absorption by a material microwave radiation field (25) within said holding and ex- (102) of the sample (2) and in particular for thereby re- posing space (15), (ii) a microwave radiation generating leasing by or from said sample (2) upon heating said and/or releasing unit (20) configured to release the mi- sample (2) at least one aerosol, in particular in a or as a crowave radiation field (25) to said holding and exposing inhalation, vaporizer and/or smoking product or device space (15), and (iii) an impedance matching unit (30) (1’), in particular for medical and/or pulmonary drug de- configured to achieve impedance matching between the livery applications. The microwave heating unit (1) com- holding and exposing space (15) and the microwave ra- prises (i) a sample holding and exposing unit (10) con- diation field (25). EP 3 747 289 A1 Printed by Jouve, 75001 PARIS (FR) 1 EP 3 747 289 A1 2 Description (iv) a free running oscillator which is configured to generate, and supply said microwave and/or RF ra- [0001] The present invention refers to microwave heat- diation field and/or said underlying microwave and/or ing units and methods which are in particular configured RF radiation signal. for heating an aerosol-forming sample due to microwave 5 absorption by a material of the sample and in particular [0007] By these measures a comparable high degree for thereby releasing by or from said sample upon heating of reliability of the heating process can be achieved, in said sample at least one aerosol and/or in a or as a in- particular in terms of rapidity, uniformity and/or complete- halation, vaporizer and/or smoking product or device, in ness. This is in particular achieved by means of a con- particular for medical and/or pulmonary drug delivery ap- 10 tactless and/or non-the resistive heating process under- plications. line the invention’s microwave heating unit and method. [0002] There are devices as consumer products [0008] According to a preferred embodiment of the in- known, for instance such as E-cigarettes or the like, which vention’s microwave heating unit said sample holding are configured in order to release an aerosol from a sam- and exposing unit comprises a sample holder defining ple due to heating. However, these known devices suffer 15 and forming said holding and exposing space within an from incomplete, non-uniform and/or comparable slow interior, in particular as a cavity, by means of first and heating of the sample. Accordingly, the required temper- second holding portions and/or first and second holding ature and/or temperature distribution cannot be achieved portions separated by a slit structure. for realizing a suitable heating process in order to serve [0009] Advantageously the impedance matching unit all the consumers requirements. 20 and in particular an impedance matching network thereof [0003] It is an object underlying the present invention is or are tunable in its matching properties concerning at to provide alternative microwave heating units and meth- least one of impedance, frequency and the aerosol-form- ods which have improved heating and thus aerosol re- ing sample. By these measures the effectiveness and/or leasing capabilities. uniformity of the microwave heating process can be fur- [0004] The object underlying the present invention is 25 ther improved. achieved by microwave heating unit according to inde- [0010] The impedance matching unit and in particular pendent claim 1 and by a microwave heating method an impedance matching network thereof may comprise according to independent claim 12. Preferred embodi- at least one of ments are defined in the respective dependent claims. [0005] According to a first aspect of the present inven- 30 - electrodes for generating the microwave radiation tion a microwave and/or RF (radio frequency) heating field upon receipt of an underlying microwave radi- unit for heating an aerosol-forming sample due to micro- ation signal and/or which geometrically fit to the aer- wave and/or RF absorption by a material of the sample osol-forming sample, holding and exposing space and in particular for thereby releasing by or from said and/or a or the cavity thereof, sample upon heating said sample at least one aerosol is 35 provided, in particular in a or as a inhalation, vaporizer - an output which contains waveguide structures, and/or smoking product or device, in particular for pul- transmission lines and/or stubs, monary drug delivery. [0006] The microwave and/or RF heating unit accord- - 1/8 λ to 1/4 λ wave guide matching elements, where- ing to the present invention comprises: 40 in λ denotes the wavelength of the underlying micro- wave radiation, and (i) a sample holding and exposing unit configured to receive and hold a sample in a holding and exposing - one or plural dielectric material portions, space and to expose the sample to a microwave ra- diation field within said holding and exposing space, 45 by means of which the impedance matching unit is in particular tunable in its properties. (ii) a microwave radiation and/or RF unit configured [0011] Further additionally or alternatively the micro- to supply the microwave and/or RF radiation field wave radiation unit may be or may comprise one or plural and/or an underlying microwave and/or RF radiation microwave radiation sources and/or microwave radiation signal to said holding and exposing space, 50 signal sources, in particular in the form of solid-state mi- and at least one of crowave sources or and/or microwave radiation signal sources, respectively. (iii) an impedance matching unit configured to [0012] Further additionally or alternatively a connect- achieve impedance matching between the holding ing configuration regarding such one or plural microwave and exposing space and the microwave and/or RF 55 radiation sources and/or microwave radiation signal radiation field and/or the underlying microwave sources may be provided, set connecting configuration and/or RF radiation signal and having a connector and/or a waveguide for providing con- nection to the respective source. 2 3 EP 3 747 289 A1 4 [0013] Said one or plural microwave radiation (signal) lator at least one of sources and/or solid-state microwave (signal) sources may be configured such that upon energization they are - is connected to the sample holding and exposing capable of generating and/or releasing said underlying unit or is a part thereof, microwave radiation field and/or said microwave radia- 5 tion field signal. - is, comprises and/or realizes an IQ modulator and/or [0014] Accordingly, a power source unit may be pro- the functionality of an IQ modulator which means the vided which is configured in order to energize the under- ability of controlling the phase and / or the gain and lying microwave radiation unit and in particular the one or plural microwave radiation (signal) sources and which 10 - comprises within a feedback loop a or the transistor in particular comprises one or plural DC power sources. amplifier, an or the impedance matching unit and/or [0015] Said microwave radiation unit and in particular impedance matching network and a or the ampli- a microwave radiation (signal) source thereof may be or tude/phase correction device. may comprise a transistor amplifier. [0016] The impedance matching unit and in particular 15 [0023] The operation and thus the oscillation process an impedance matching network thereof may be or may of the free running oscillator is initiated by the statistical comprise a microwave feedback port and/or a microwave and/or stochastic properties and in particular by noise of signal feedback port which is connected to an input of the overall electric circuit. Amplitude, phase and gain the transistor amplifier in order to meet an underlying properties are defined by the electric properties of the oscillation condition. 20 further components and/or geometry and material por- [0017] Under such circumstances it is of particular ad- tions of the sample, the sample holding and exposing vantage if an additional smart phase and/or an amplitude means and in particular the sample holder with the hold- correction device is or are connected in between the feed- ing and exposing space and in particular the cavity and back port and the input of the transistor amplifier. the impedance matching unit and network, for instance [0018] The microwave radiation generating and/or re- 25 the slit structure and any dielectric. leasing unit and in particular a microwave source thereof [0024] In general and in an initial stage of the oscillation may be or may comprise a transistor amplifier and in process, all frequency components are contained ac- particular may have an input that is connected to an out- cording to its ratio within the noise spectrum.
Load more

Recommended publications
  • Protabase Record Display Datura Stramonium L
    Protabase Record display www.prota.org Datura stramonium L. Protologue Sp. pl. 1: 179 (1753). Family Solanaceae Chromosome number 2n = 24 Vernacular names Thorn apple, green thorn apple, Jimson weed, Jamestown weed, devil’s apple, devil’s trumpet, stramonium (En). Pomme épineuse, stramoine, datura, feuille du diable, herbe du diable (Fr). Figueira do inferno, pomo espinhoso, erva dos bruxos, palha verde, estramonio (Po). Muranha (Sw). Origin and geographic distribution Datura stramonium is native to the Americas and has been introduced in many tropical, subtropical and even temperate regions. It is a naturalized weed in many African countries, but is probably seriously under-reported. Uses Datura stramonium and Datura metel L. have largely similar medicinal uses throughout the world. The most widely known use of Datura stramonium and of other Datura species is for relieving asthma, cough, tuberculosis and bronchitis by smoking the dried leaves, roots or flowers. ‘Asthma cigarettes’ have been shown to be very effective in some cases, but in other cases they had little or no effect. Cigarettes made with the leaves are also used to treat Parkinson’s disease. A decoction or infusion of leaves is given as a sedative to mental and schizophrenic patients. The leaves are applied as a dressing to cure rheumatic pain, swellings, wounds, gout, burns, ingrown toe-nails, fungal infections, tumours and ulcers. Dried pulverized leaves are dusted on wounds or applied after mixing the powder with fat or Vaseline. In DR Congo pounded fresh root and fresh leaves are soaked in water and the liquid is given in enema as an abortifacient.
    [Show full text]
  • Nightshade”—A Hierarchical Classification Approach to T Identification of Hallucinogenic Solanaceae Spp
    Talanta 204 (2019) 739–746 Contents lists available at ScienceDirect Talanta journal homepage: www.elsevier.com/locate/talanta Call it a “nightshade”—A hierarchical classification approach to T identification of hallucinogenic Solanaceae spp. using DART-HRMS-derived chemical signatures ∗ Samira Beyramysoltan, Nana-Hawwa Abdul-Rahman, Rabi A. Musah Department of Chemistry, State University of New York at Albany, 1400 Washington Ave, Albany, NY, 12222, USA ARTICLE INFO ABSTRACT Keywords: Plants that produce atropine and scopolamine fall under several genera within the nightshade family. Both Hierarchical classification atropine and scopolamine are used clinically, but they are also important in a forensics context because they are Psychoactive plants abused recreationally for their psychoactive properties. The accurate species attribution of these plants, which Seed species identifiction are related taxonomically, and which all contain the same characteristic biomarkers, is a challenging problem in Metabolome profiling both forensics and horticulture, as the plants are not only mind-altering, but are also important in landscaping as Direct analysis in real time-mass spectrometry ornamentals. Ambient ionization mass spectrometry in combination with a hierarchical classification workflow Chemometrics is shown to enable species identification of these plants. The hierarchical classification simplifies the classifi- cation problem to primarily consider the subset of models that account for the hierarchy taxonomy, instead of having it be based on discrimination between species using a single flat classification model. Accordingly, the seeds of 24 nightshade plant species spanning 5 genera (i.e. Atropa, Brugmansia, Datura, Hyocyamus and Mandragora), were analyzed by direct analysis in real time-high resolution mass spectrometry (DART-HRMS) with minimal sample preparation required.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • (DMT), Harmine, Harmaline and Tetrahydroharmine: Clinical and Forensic Impact
    pharmaceuticals Review Toxicokinetics and Toxicodynamics of Ayahuasca Alkaloids N,N-Dimethyltryptamine (DMT), Harmine, Harmaline and Tetrahydroharmine: Clinical and Forensic Impact Andreia Machado Brito-da-Costa 1 , Diana Dias-da-Silva 1,2,* , Nelson G. M. Gomes 1,3 , Ricardo Jorge Dinis-Oliveira 1,2,4,* and Áurea Madureira-Carvalho 1,3 1 Department of Sciences, IINFACTS-Institute of Research and Advanced Training in Health Sciences and Technologies, University Institute of Health Sciences (IUCS), CESPU, CRL, 4585-116 Gandra, Portugal; [email protected] (A.M.B.-d.-C.); ngomes@ff.up.pt (N.G.M.G.); [email protected] (Á.M.-C.) 2 UCIBIO-REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal 3 LAQV-REQUIMTE, Laboratory of Pharmacognosy, Department of Chemistry, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal 4 Department of Public Health and Forensic Sciences, and Medical Education, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal * Correspondence: [email protected] (D.D.-d.-S.); [email protected] (R.J.D.-O.); Tel.: +351-224-157-216 (R.J.D.-O.) Received: 21 September 2020; Accepted: 20 October 2020; Published: 23 October 2020 Abstract: Ayahuasca is a hallucinogenic botanical beverage originally used by indigenous Amazonian tribes in religious ceremonies and therapeutic practices. While ethnobotanical surveys still indicate its spiritual and medicinal uses, consumption of ayahuasca has been progressively related with a recreational purpose, particularly in Western societies. The ayahuasca aqueous concoction is typically prepared from the leaves of the N,N-dimethyltryptamine (DMT)-containing Psychotria viridis, and the stem and bark of Banisteriopsis caapi, the plant source of harmala alkaloids.
    [Show full text]
  • Fall TNP Herbals.Pptx
    8/18/14 Introduc?on to Objecves Herbal Medicine ● Discuss history and role of psychedelic herbs Part II: Psychedelics, in medicine and illness. Legal Highs, and ● List herbs used as emerging legal and illicit Herbal Poisons drugs of abuse. ● Associate main plant and fungal families with Jason Schoneman RN, MS, AGCNS-BC representave poisonous compounds. The University of Texas at Aus?n ● Discuss clinical management of main toxic Schultes et al., 1992 compounds. Psychedelics Sacraments: spiritual tools or sacred medicine by non-Western cultures vs. Dangerous drugs of abuse vs. Research and clinical tools for mental and physical http://waynesword.palomar.edu/ww0703.htm disorders History History ● Shamanic divinaon ○ S;mulus for spirituality/religion http://orderofthesacredspiral.blogspot.com/2012/06/t- mckenna-on-psilocybin.html http://www.cosmicelk.net/Chukchidirections.htm 1 8/18/14 History History http://www.10zenmonkeys.com/2007/01/10/hallucinogenic- weapons-the-other-chemical-warfare/ http://rebloggy.com/post/love-music-hippie-psychedelic- woodstock http://fineartamerica.com/featured/misterio-profundo-pablo- amaringo.html History ● Psychotherapy ○ 20th century: un;l 1971 ● Recreaonal ○ S;mulus of U.S. cultural revolu;on http://qsciences.digi-info-broker.com http://www.uspharmacist.com/content/d/feature/c/38031/ http://en.wikipedia.org/nervous_system 2 8/18/14 Main Groups Main Groups Tryptamines LSD, Psilocybin, DMT, Ibogaine Other Ayahuasca, Fly agaric Phenethylamines MDMA, Mescaline, Myristicin Pseudo-hallucinogen Cannabis Dissociative
    [Show full text]
  • Postoperative Pain
    LONDON, SATURDAY 19 AUGUST 1978 MEDICAL Br Med J: first published as 10.1136/bmj.2.6136.517 on 19 August 1978. Downloaded from JOURNAL Postoperative pain It is an indictment of modern medicine that an apparently carries marginally less risk of depressing respiration or of simple problem such as the reliable relief of postoperative inducing nausea or vomiting. Nevertheless, it does produce pain remains largely unsolved. Numerous patients will bear psychotomimetic side effects, which are related to the dose. testimony to our shortcomings: indeed, after talking to their These reduce its value in the prolonged treatment of very friends, many will expect pain after their operation. At whose severe pain. door can we lay the responsibility-the patients, the doctors, Meptazinol is a new opiate antagonist which produces the nurses, or the pharmaceutical industry ? postoperative analgesia similar to that obtained with pethidine The patients themselves must take a fair share of the and pentazocine.4 Its potency, milligram for milligram, is blame. In no symptom are they more inconsistent and un- similar to pethidine's but its action and sedative effect are reliable. After identical operations under identical anaesthetics somewhat shorter. Cardiovascular performance is not reduced carried out by the same specialists, two patients in the same and respiration is thought to be less affected than with ward may apparently experience entirely different degrees pethidine. The main potential advantage, however, is that in of pain. Personality differences may account for some of the animal studies it has shown a low dependence potential.5 If variations, but we certainly do not understand these well these non-addictive properties are confirmed in man and enough confidently to provide each individual with exactly further clinical trials show no psychotomimetic side effects, http://www.bmj.com/ what he or she needs.
    [Show full text]
  • Veterinary Anesthetic and Analgesic Formulary 3Rd Edition, Version G
    Veterinary Anesthetic and Analgesic Formulary 3rd Edition, Version G I. Introduction and Use of the UC‐Denver Veterinary Formulary II. Anesthetic and Analgesic Considerations III. Species Specific Veterinary Formulary 1. Mouse 2. Rat 3. Neonatal Rodent 4. Guinea Pig 5. Chinchilla 6. Gerbil 7. Rabbit 8. Dog 9. Pig 10. Sheep 11. Non‐Pharmaceutical Grade Anesthetics IV. References I. Introduction and Use of the UC‐Denver Formulary Basic Definitions: Anesthesia: central nervous system depression that provides amnesia, unconsciousness and immobility in response to a painful stimulation. Drugs that produce anesthesia may or may not provide analgesia (1, 2). Analgesia: The absence of pain in response to stimulation that would normally be painful. An analgesic drug can provide analgesia by acting at the level of the central nervous system or at the site of inflammation to diminish or block pain signals (1, 2). Sedation: A state of mental calmness, decreased response to environmental stimuli, and muscle relaxation. This state is characterized by suppression of spontaneous movement with maintenance of spinal reflexes (1). Animal anesthesia and analgesia are crucial components of an animal use protocol. This document is provided to aid in the design of an anesthetic and analgesic plan to prevent animal pain whenever possible. However, this document should not be perceived to replace consultation with the university’s veterinary staff. As required by law, the veterinary staff should be consulted to assist in the planning of procedures where anesthetics and analgesics will be used to avoid or minimize discomfort, distress and pain in animals (3, 4). Prior to administration, all use of anesthetics and analgesic are to be approved by the Institutional Animal Care and Use Committee (IACUC).
    [Show full text]
  • HANDBOOK of Medicinal Herbs SECOND EDITION
    HANDBOOK OF Medicinal Herbs SECOND EDITION 1284_frame_FM Page 2 Thursday, May 23, 2002 10:53 AM HANDBOOK OF Medicinal Herbs SECOND EDITION James A. Duke with Mary Jo Bogenschutz-Godwin Judi duCellier Peggy-Ann K. Duke CRC PRESS Boca Raton London New York Washington, D.C. Peggy-Ann K. Duke has the copyright to all black and white line and color illustrations. The author would like to express thanks to Nature’s Herbs for the color slides presented in the book. Library of Congress Cataloging-in-Publication Data Duke, James A., 1929- Handbook of medicinal herbs / James A. Duke, with Mary Jo Bogenschutz-Godwin, Judi duCellier, Peggy-Ann K. Duke.-- 2nd ed. p. cm. Previously published: CRC handbook of medicinal herbs. Includes bibliographical references and index. ISBN 0-8493-1284-1 (alk. paper) 1. Medicinal plants. 2. Herbs. 3. Herbals. 4. Traditional medicine. 5. Material medica, Vegetable. I. Duke, James A., 1929- CRC handbook of medicinal herbs. II. Title. [DNLM: 1. Medicine, Herbal. 2. Plants, Medicinal.] QK99.A1 D83 2002 615′.321--dc21 2002017548 This book contains information obtained from authentic and highly regarded sources. Reprinted material is quoted with permission, and sources are indicated. A wide variety of references are listed. Reasonable efforts have been made to publish reliable data and information, but the author and the publisher cannot assume responsibility for the validity of all materials or for the consequences of their use. Neither this book nor any part may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, microfilming, and recording, or by any information storage or retrieval system, without prior permission in writing from the publisher.
    [Show full text]
  • 800.438.7199 Fax: 805.964.1329 Local: 805.683.1561 Web: on Facebook.Com/Sanmarcosgrowers
    Toll Free: 800.438.7199 Fax: 805.964.1329 Local: 805.683.1561 Web: www.smgrowers.com On facebook.com/SanMarcosGrowers Since 1979, when San Marcos Growers first began, we have always strived to provide California's independent retail garden centers and landscape professionals with well grown, high quality plants, that are appropriate to California's mediterranean climate. After thirty two years, this still remains our primary goal. Others may be focusing elsewhere, but we remain firmly committed to the independent retailers and landscape professionals that have long been loyal to us. We thank our customers for their continued business and offer them this 2011 catalog with many exciting new plants, but no overall price increases. We also remain committed to the fact that water remains a precious and limited commodity. To this end we continue to expand our line of water conserving succulents and plants from mediterranean climates, including many from our own California flora. This catalog has 145 new plants, which are all listed at the back of this catalog and are accompanied within the catalog body with a star ( ). Of these new plants, 56 are succulents, bringing the total number of succulents we now grow to 379, and 29 are California native plants, bringing our total of native plants to 156. We also are proud to offer 9 new plants from the UC Santa Cruz Koala Blooms Australian Native Plant program and so now are growing 29 great plants from this program and bringing to 190 the total number of different Australian plants that we currently grow.
    [Show full text]
  • The Experience Elicited by Hallucinogens Presents the Highest Similarity to Dreaming Within a Large Database of Psychoactive Substance Reports
    ORIGINAL RESEARCH published: 22 January 2018 doi: 10.3389/fnins.2018.00007 The Experience Elicited by Hallucinogens Presents the Highest Similarity to Dreaming within a Large Database of Psychoactive Substance Reports Camila Sanz 1, Federico Zamberlan 1, Earth Erowid 2, Fire Erowid 2 and Enzo Tagliazucchi 1,3* 1 Departamento de Física, Universidad de Buenos Aires, Buenos Aires, Argentina, 2 Erowid Center, Grass Valley, CA, United States, 3 Brain and Spine Institute, Paris, France Ever since the modern rediscovery of psychedelic substances by Western society, Edited by: several authors have independently proposed that their effects bear a high resemblance Rick Strassman, to the dreams and dreamlike experiences occurring naturally during the sleep-wake University of New Mexico School of cycle. Recent studies in humans have provided neurophysiological evidence supporting Medicine, United States this hypothesis. However, a rigorous comparative analysis of the phenomenology (“what Reviewed by: Matthias E. Liechti, it feels like” to experience these states) is currently lacking. We investigated the semantic University Hospital Basel, Switzerland similarity between a large number of subjective reports of psychoactive substances and Michael Kometer, University of Zurich, Switzerland reports of high/low lucidity dreams, and found that the highest-ranking substance in *Correspondence: terms of the similarity to high lucidity dreams was the serotonergic psychedelic lysergic Enzo Tagliazucchi acid diethylamide (LSD), whereas the highest-ranking in terms of the similarity to dreams [email protected] of low lucidity were plants of the Datura genus, rich in deliriant tropane alkaloids. Specialty section: Conversely, sedatives, stimulants, antipsychotics, and antidepressants comprised most This article was submitted to of the lowest-ranking substances.
    [Show full text]
  • Medication Safety in High-Risk Situations
    Medication Safety in High-risk Situations Technical Report Medication Safety in High-risk Situations Technical Report WHO/UHC/SDS/2019.10 © World Health Organization 2019 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/rules). Suggested citation. Medication Safety in High-risk Situations. Geneva: World Health Organization; 2019 (WHO/UHC/SDS/2019.10). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.
    [Show full text]
  • Opioid Analgesics and the Gastrointestinal Tract
    NUTRITION ISSUES IN GASTROENTEROLOGY, SERIES #64 Carol Rees Parrish, R.D., M.S., Series Editor Opioid Analgesics and the Gastrointestinal Tract Lingtak-Neander Chan Opioids have been used to manage pain and other ailments for centuries. The consti- pating effects of opioid analgesic agents are well known and can be used to manage severe diarrhea and control high output ostomies. Loperamide, diphenoxylate, and difenoxin are currently the only opioid-derivatives approved by the FDA for treating diarrhea. Drug-drug interactions and end organ dysfunction may exacerbate systemic side effects of these drugs. In patients who have failed to respond to these agents, other systemic opioids may be considered. The goal of therapy to control gastrointestinal secretion should be to use the lowest effective dose with minimal side effects. Careful monitoring for systemic side effects during the initiation and dose titration phase are crucial to minimize the risks associated wtih opioid use. INTRODUCTION Sumerian clay tablets inscribed in Cuneiform script he term “opioid” refers to a large group of com- about 3000 B.C. Opium was probably used as an pounds and chemicals that share the characteris- euphoriant in religious rituals by the Sumerians (1,2). Ttics of opium. Opium, from the Greek word During the Middle Ages, after opium was introduced “opos” for juice, refers to the liquid collected from the to Asia and Europe, more extensive documentation of unripe seed capsule of Papaver somniferum L., also opium use became available. It wasn’t until 1805, that known as opium poppy. Opium has been used for med- a young German apothecary named Friedrich Wilhelm icinal purposes for centuries.
    [Show full text]